一种用于克服非小细胞肺癌治疗中抗原异质性的多靶向 CAR-T 细胞平台
A Multi-Targeting Chimeric Antigen Receptor-T Cell Platform to Overcome Antigen Heterogeneity in the Treatment of Non-Small Cell Lung Cancer.
这些发现支持采用多靶点CAR-T 策略来应对NSCLC及可能其他实体瘤中的抗原异质性。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题:Distinct tumor-infiltrating lymphocyte landscapes are associated with clinical outcomes in localized non-small-cell lung cancer.
Distinct tumor-infiltrating lymphocyte landscapes are associated with clinical outcomes in localized non-small-cell lung cancer.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
我们的研究表明,尽管浸润性 T 细胞的数量与患者生存无关,但浸润性 T 细胞的性质,即分为不同的 TIL 免疫类型,在 NSCLC 中具有预后相关性,并可能为临床治疗策略提供依据。
尽管肿瘤浸润性T淋巴细胞(TILs)在癌症生物学中具有重要意义,但TIL表型与局限性非小细胞肺癌(NSCLC)预后相关性之间的关系尚未得到充分确立。
新鲜肿瘤组织及正常癌旁组织前瞻性采集自150例局限性NSCLC患者。组织通过TIL的高维流式细胞术进行全面表征,并整合了多重免疫荧光、T细胞受体测序、外显子组测序、RNA测序、靶向蛋白质组学及临床病理特征的免疫基因组学数据。
尽管TIL浸润的程度或特定TIL亚群单独均无显著预后意义,但整合高维流式细胞术数据识别出两种主要免疫类型(IM1和IM2),它们可独立于临床特征预测无复发生存期。IM2与不良预后相关,其特征是存在增殖性TIL,表达分化簇103、程序性细胞死亡蛋白1、T细胞免疫球蛋白和黏蛋白结构域包含蛋白3以及诱导性T细胞共刺激分子。相反,IM1与良好预后相关,其区分特征为大量表达溶细胞酶的CD8+ T细胞、缺乏抑制性受体表达的CD4+ T细胞,以及B细胞浸润和三级淋巴结构水平升高。虽然B细胞浸润增加与良好预后相关,但预后最佳的是肿瘤中B细胞和T细胞均呈高水平的患者。这些发现已在癌症基因组图谱的患者肿瘤中得到验证。
Despite the importance of tumor-infiltrating T lymphocytes (TILs) in cancer biology, the relationship between TIL phenotypes and their prognostic relevance for localized non-small-cell lung cancer (NSCLC) has not been well established.
Fresh tumor and normal adjacent tissue was prospectively collected from 150 patients with localized NSCLC. Tissue was comprehensively characterized by high-dimensional flow cytometry of TILs integrated with immunogenomic data from multiplex immunofluorescence, T-cell receptor sequencing, exome sequencing, RNA sequencing, targeted proteomics, and clinicopathologic features.
While neither the magnitude of TIL infiltration nor specific TIL subsets were significantly prognostic alone, the integration of high-dimensional flow cytometry data identified two major immunotypes (IM1 and IM2) that were predictive of recurrence-free survival independent of clinical characteristics. IM2 was associated with poor prognosis and characterized by the presence of proliferating TILs expressing cluster of differentiation 103, programmed cell death protein 1, T-cell immunoglobulin and mucin-domain containing protein 3, and inducible T-cell costimulator. Conversely, IM1 was associated with good prognosis and differentiated by an abundance of CD8 + T cells expressing cytolytic enzymes, CD4 + T cells lacking the expression of inhibitory receptors, and increased levels of B-cell infiltrates and tertiary lymphoid structures. While increased B-cell infiltration was associated with good prognosis, the best prognosis was observed in patients with tumors exhibiting high levels of both B cells and T cells. These findings were validated in patient tumors from The Cancer Genome Atlas.
Our study suggests that although the number of infiltrating T cells is not associated with patient survival, the nature of the infiltrating T cells, resolved in distinct TIL immunotypes, is prognostically relevant in NSCLC and may inform therapeutic approaches to clinical care.
在 PubMed 查看 → 出版商原文(DOI) 全文 PDF(PMC)· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →
MEMBER ACCOUNT
登录成功会直接打开下一页。